Recombinant Human IL‑28A/IFN‑ lambda 2 (Catalog # 1587‑IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant HumanIL‑28A/IFN‑ lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587). The ND50 is typically 0.3-1.5 µg/mL.
IL‑28A/IFN‑ lambda 2 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Goat Anti-HumanIL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.